• 1
    Arnow BA, Hunkeler EM, Blasey CM et al. Comorbid depression, chronic pain, and disability in primary care. Psychosom. Med. 2006; 68: 262268.
  • 2
    Simon GE, VonKorff M, Piccinelli M et al. An international study of the relation between somatic symptoms and depression. N. Engl. J. Med. 1999; 341: 13291335.
  • 3
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Press, Washington, DC, 1994.
  • 4
    Bair MJ, Robinson RL, Eckert GJ et al. Impact of pain on depression treatment response in primary care. Psychosom. Med. 2004; 66: 1722.
  • 5
    Fava M, Mallinckrodt CH, Detke MJ et al. The effect of duloxetine on painful physical symptoms in depressed patients: Do improvements in these symptoms result in higher remission rates? J. Clin. Psychiatry 2004; 65: 521530.
  • 6
    Jenner PN. Paroxetine: An overview of dosage, tolerability, and safety. Int. Clin. Psychopharmacol. 1992; 6 (Suppl. 4): 6980.
  • 7
    Warrington SJ. Clinical implications of the pharmacology of serotonin reuptake inhibitors. Int. Clin. Psychopharmacol. 1992; 7 (Suppl. 2): 1319.
  • 8
    Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability. J. Affect. Disord. 2000; 58: 1936.
  • 9
    Mace S, Taylor D. Selective serotonin reuptake inhibitors: A review of efficacy and tolerability in depression. Expert Opin. Pharmacother. 2000; 1: 917933.
  • 10
    Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 2001; 178: 234241.
  • 11
    Greco T, Eckert G, Kroenke K. The outcome of physical symptoms with treatment of depression. J. Gen. Intern. Med. 2004; 19: 813818.
  • 12
    Karp JF, Scott J, Houck P et al. Pain predicts longer time to remission during treatment of recurrent depression. J. Clin. Psychiatry 2005; 66: 591597.
  • 13
    Fava M. Depression with physical symptoms: Treating to remission. J. Clin. Psychiatry 2003; 64 (Suppl. 7): 2428.
  • 14
    Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001; 25: 871880.
  • 15
    Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. J. Clin. Psychiatry 2002; 63: 308315.
  • 16
    Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J. Psychiatr. Res. 2002; 36: 383390.
  • 17
    Goldstein DJ, Mallinckrodt C, Lu Y, Detke M, Demitrack MA. Efficacy and safety of duloxetine 120 mg/day in the treatment of depression. J. Affect. Disord. 2002; 68: 108 (Abstract).
  • 18
    Goldstein DJ, Lu Y, Detke M, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine. Eur. Neuropsychopharmacol. 2000; 12 (Suppl. 2): 4344.
  • 19
    Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial. J. Clin. Psychiatry 2002; 63: 225231.
  • 20
    Goldstein DJ, Lu Y, Detke MJ et al. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004; 45: 1728.
  • 21
    Detke MJ, Wiltse CG, Mallinckrodt CH et al. Duloxetine in the acute and long-term treatment of major depressive disorder: A placebo- and paroxetine-controlled trial. Eur. Neuropsychopharmacol. 2004; 14: 457470.
  • 22
    Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960; 23: 5662.
  • 23
    Hamilton M. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol 1967; 6: 278296.
  • 24
    Bailey RK, Mallinckrodt CH, Wohlreich MM et al. Duloxetine in the treatment of major depressive disorder: Comparisons of safety and efficacy. J. Natl Med. Assoc. 2006; 98: 437447.
  • 25
    Piaggio G, Elbourne DR, Altman DG et al. Reporting of noninferiority and equivalence randomized trials: An extension of the CONSORT statement. JAMA 2006; 295: 11521160.
  • 26
    Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health and Human Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Rockville, MD, 1976.
  • 27
    Hamilton M. The assessment of anxiety states by rating. Br. J. Psychiatry 1959; 32: 5055.
  • 28
    Barsky AJ, Wyshak G, Klerman GL. Hypochondriasis. An evaluation of the DSM-III criteria in medical outpatients. Arch. Gen. Psychiatry 1986; 43: 493500.
  • 29
    DeLoach LJ, Higgins MS, Caplan AB et al. The visual analog scale in the immediate postoperative period: Intrasubject variability and correlation with a numeric scale. Anesth. Analg. 1998; 86: 102106.
  • 30
    Thompson WL, Brunelle RL, Enas GG, Simpson PJ. Routine Laboratory Tests in Clinical Trials. Eli Lilly and Company, Indianapolis, IN, 1990.
  • 31
    Mallinckrodt CH, Prakash A, Andorn AC et al. Duloxetine for the treatment of major depressive disorder: A closer look at efficacy and safety data across the approved dose range. J. Psychiatr. Res. 2006; 40: 337348.
  • 32
    Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J. Biopharm. Stat. 2001; 11: 921.
  • 33
    Mallinckrodt CH, Goldstein DJ, Detke MJ et al. Duloxetine: A new treatment for the emotional and physical symptoms of depression. Prim. Care Companion J. Clin. Psychiatry 2003; 5: 1928.
  • 34
    Dunner DL, Dunbar GC. Optimal dose regimen for paroxetine. J. Clin. Psychiatry 1992; 53 (Suppl.): 2126.
  • 35
    Perahia DG, Wang F, Mallinckrodt CH et al. Duloxetine in the treatment of major depressive disorder: A placebo- and paroxetine-controlled trial. Eur. Psychiatry 2006; 21: 367378.
  • 36
    Bech P. Acute therapy of depression. J. Clin. Psychiatry 1993; 54 (Suppl.): 1827.
  • 37
    Anderson IM. Meta-analytical studies on new antidepressants. Br. Med. Bull. 2001; 57: 161178.
  • 38
    Mulrow CD, Williams JW Jr, Chiquette E et al. Efficacy of newer medications for treating depression in primary care patients. Am. J. Med. 2000; 108: 5464.
  • 39
    Brannan SK, Mallinckrodt CH, Brown EB et al. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J. Psychiatr. Res. 2005; 39: 4353.
  • 40
    Goldstein DJ, Lu Y, Detke MJ et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116: 109118.
  • 41
    Arnold LM, Rosen A, Pritchett YL et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119: 515.
  • 42
    Perahia DG, Kajdasz DK, Walker DJ et al. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder. Int. J. Clin. Pract. 2006; 60: 613620.
  • 43
    Nelson JC, Lu PY, Martynov O et al. The safety and tolerability of duloxetine compared with paroxetine and placebo: A pooled analysis of 4 clinical trials. Prim. Care Companion J. Clin. Psychiatry 2006; 8: 212219.
  • 44
    Greist J, McNamara RK, Mallinckrodt CH et al. Incidence and duration of antidepressant-induced nausea: Duloxetine compared with paroxetine and fluoxetine. Clin. Ther. 2004; 26: 14461455.